In 4 major subgroups rida demonstrated significantly higher activity with CBR of 30%, 33%, 30%, and 23% for bone sarcoma, leiomyosarcoma, liposarcoma and other, respectively. So we can conclude that rida is active in pts whose disease is progressing, however, the phase 3 trial enrolled pts who were disease stable so no direct comparison with the phase 2 results is possible.
However, I would argue that in rida's p2 trial, ariad was able to identify an opportunity to treat sarcoma in a maintenance setting for pts who are disease stable following a favorable response to chemotherapy. The fact that 29% (61 of 212) patients in the Phase 2 trial achieved a PFS rate at six months of 70% which was "nearly triple that of the overall population" cannot be easily explained away.